Original Research
Accepted on 02 Oct 2024
Ustekinumab affects myofibroblast metabolism to alleviate intestinal fibrosis by targeting KDELC1 in Crohn's disease through multimachine learning combined with single-cell sequencing analysis
in Gastroenterology